Thelansis

  High-grade B-cell lymphoma (HGBL) is a newly introduced classification in the 2016 World Health Organization (WHO) revision. It replaces "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (BCLU, DLBCL/BL)." HGBL includes two types: HGBL with MYC and BCL2 and BCL6 rearrangements (HGBL, R or double/triple-hit lymphoma) and high-grade B-cell lymphomas not otherwise specified (HGBL, NOS). HGBL NOS lacks MYC and BCL2 or BCL6 gene rearrangements but has morphological features between DLBCL and BL. Patients with HGBL typically present with widespread disease involvement. HGBL, NOS is considered a gray zone lymphoma, encountered infrequently in clinics, with unclear etiology and pathogenesis. DLBCL/HGBL-MYC/BCL2 are aggressive lymphomas with an unfavorable prognosis. BCL2 and BCL6 rearrangements independently negatively impact survival, especially in the first two years. DLBCL-like morphology has a ...